A new study has identified key blood proteins that could predict the onset of dementia years before symptoms appear, offering hope for earlier intervention in one of the most challenging public health issues of our time. The research, conducted by a team of scientists from Fudan University and published in Nature Aging, utilised data from over 52,000 adults in the UK Biobank. The study underscores the potential of specific plasma proteins as biomarkers, providing a new avenue for dementia risk assessment and early intervention strategies.
The study looked at how well four plasma proteins could predict what would happen: GFAP (glial fibrillary acidic protein), NEFL (neurofibrillary light chain), GDF15 (growth differentiation factor 15), and LTBP2 (latent transforming growth factor beta-binding protein 2). These proteins were found to be strongly associated with the risk of developing all-cause dementia (ACD), Alzheimer’s disease (AD), and vascular dementia (VaD). Remarkably, the levels of GFAP and NEFL began to change at least ten years before the clinical diagnosis of dementia, making them powerful indicators of future cognitive decline.
GFAP emerged as the most significant biomarker, with individuals exhibiting higher levels being 2.32 times more likely to develop dementia. The study also found that using GFAP along with demographic information made very good predictions for ACD, AD, and VaD, with an area under the curve (AUC) value of up to 0.912, which means the predictions were very accurate.
The ability to predict dementia onset a decade or more before symptoms manifest is particularly crucial given the current lack of effective treatments for dementia. Early detection could enable more timely interventions, potentially slowing disease progression and improving patient outcomes. The findings suggest that blood tests measuring GFAP and NEFL could be integrated into routine screenings for those at high risk of dementia, paving the way for more personalised and proactive healthcare strategies.
The study’s authors also pointed out that GFAP and LTBP2 were only found in people with dementia. These proteins did not have any significant links to other neurodegenerative or neurological conditions, which further supports their usefulness as biomarkers for dementia. This specificity could reduce false positives and improve the accuracy of dementia screening programmes.
This study represents a significant advance in dementia research, moving beyond previous efforts that typically focused on a small number of biomarkers. By using a large-scale, data-driven proteomic approach, the researchers were able to identify and validate a set of proteins that show strong predictive potential for dementia.
The research team emphasised the need for further studies to explore the mechanisms by which these proteins influence dementia risk. They also highlighted the potential for these biomarkers to be used in conjunction with other diagnostic tools, such as cognitive tests, to create more comprehensive and accurate predictive models.
While these findings are promising, the translation from research to clinical practice will require further validation and refinement. The study’s reliance on data from the UK Biobank, a population that tends to be healthier and younger than the general public, suggests that additional research in more diverse cohorts is needed. Moreover, the development of standardised assays for these proteins will be crucial for their widespread adoption in clinical settings.
